智通财经网·2025-09-02 13:16Core Viewpoint - Junshi Biosciences (01877) announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of JT118 injection, a recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Group 1: Product Details - JT118 is a "two-in-one" recombinant protein vaccine composed of monkeypox virus antigens A35 (extracellular membrane virus antigen) and M1 (intracellular mature virus antigen) [1] - The vaccine retains the epitope structures of both natural antigens A35 and M1 while significantly increasing molecular weight through multi-antigen fusion, which enhances immune activation [1] Group 2: Clinical Research Findings - Preclinical studies indicate that JT118 can generate high levels of binding antibodies, vaccinia virus/monkeypox virus neutralizing antibodies, and cellular immune activation in both small and large animal models [1] - The vaccine demonstrates significant protective effects against vaccinia virus/monkeypox virus infections in animal models, with good safety profiles [1]